Clinical Trials for Non-Small Cell Lung Cancer

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with advanced/metastatic solid tumors, particularly those with non-small cell lung cancer (NSCLC) harboring EGFR mutations and/or cMET aberrations, who have exhausted standard treatments. It investigates EMB-01, a bispecific antibody targeting EGFR and cMET receptors, using EpimAb's FIT-Ig® platform, with weekly administrations in 28-day cycles.

ClinicalTrials.gov ID: NCT03797391

An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score of 50% or greater, comparing pembrolizumab, a PD-1 checkpoint inhibitor, combined with sacituzumab govitecan, a Trop-2 targeted antibody-drug conjugate, versus pembrolizumab monotherapy. Eligible patients must not have had prior systemic therapy for metastatic NSCLC and should not require targeted therapies for EGFR, ALK-1, or ROS-1 mutations.

ClinicalTrials.gov ID: NCT05609968

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients aged 18 and older with advanced solid tumors, including NSCLC, melanoma, pancreatic, and ovarian cancers, who have progressed after standard treatments or are treatment-naïve. It evaluates the safety and efficacy of ONC-392, an anti-CTLA-4 monoclonal antibody, alone and combined with pembrolizumab to determine appropriate dosing for future studies.

ClinicalTrials.gov ID: NCT04140526

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced solid malignancies, evaluating the safety and efficacy of the PARP inhibitor AZD5305, both alone and combined with agents like Paclitaxel and Trastuzumab Deruxtecan, showing promising response rates and reduced hematologic toxicity.

ClinicalTrials.gov ID: NCT04644068

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial is enrolling patients with various hematological malignancies, who have been previously treated with ibrutinib, to evaluate its long-term safety and efficacy and continue ibrutinib treatment; ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor.

ClinicalTrials.gov ID: NCT01804686

Pilot Study of a Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with stage IV ALK-positive non-small cell lung cancer who have stable disease on ALK inhibitors, testing a peptide vaccine designed to stimulate T-cell responses to prevent resistance to ALK-targeted therapies.

ClinicalTrials.gov ID: NCT05950139

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates luveltamab tazevibulin, an anti-FOLR1 antibody-drug conjugate, in adult patients with previously treated advanced or metastatic non-squamous/adenocarcinoma or adenosquamous NSCLC, targeting FOLR1-expressing tumors. The study includes patients with disease progression who have undergone two to four prior systemic therapies.

ClinicalTrials.gov ID: NCT06555263

A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the combination of alirocumab, a PCSK9 inhibitor, with cemiplimab, a PD-1 inhibitor, in patients with metastatic non-small cell lung cancer who have progressed after prior PD-1 therapies. It is aimed at those with specific molecular alterations such as EGFR, ALK, and ROS1, following progression on targeted treatments.

ClinicalTrials.gov ID: NCT05553834

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the safety and preliminary anti-tumor activity of IDE397, a MAT2A inhibitor, in adult patients with MTAP-deleted advanced solid tumors, either as monotherapy or in combination with docetaxel, paclitaxel, or sacituzumab govitecan. Eligible patients must have advanced or metastatic solid tumors that have failed at least one prior treatment line.

ClinicalTrials.gov ID: NCT04794699

A Phase II Study of the Effects of Pembrolizumab on Quality of Life for Patients With Treatment-Naïve, Advanced or Metastatic NSCLC and Poor Performance Status

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates the effects of pembrolizumab on quality of life in treatment-naïve patients with advanced or metastatic NSCLC and poor performance status (ECOG 2 or 3) with a PD-L1 TPS ≥ 1%, who are unsuitable for standard treatments. Pembrolizumab, a PD-1 inhibitor, reactivates T-cells, aiming to improve outcomes and manage toxicity in this specific patient population.

ClinicalTrials.gov ID: NCT05589818